Fig. 6. Lenvatinib is more effective than anti-VEGFR2 DC101 in sensitizing gemcitabine-induced tumor response. MCA/129 fibrosarcomas tumors were implanted into the flank of a sv129BL/6 mice. When tumors reached an average of 80mm³, animals were treated every 4 days with 1600 μg/mouse DC101 or 100 mg/kg lenvatinib at 1h before 240 mg/kg of gemcitabine. In each experiment, 5 mice were used per group. Tumors were measured daily through the course of the experiment. Arrows designate treatment days. Black arrows indicate lenvatinib was prepared at time of first treatment, blue arrows indicate that lenvatinib was prepared the day of treatment. A. Collated tumor growth for Experiment #1 shows a significant difference (p<0.001) between treatment groups of lenvatinib+gemcitabine vs. gemcitabine alone. Black arrows designate treatment days. B. Individual tumor response for Experiment #1. C. Collated tumor growth for Experiment #2 shows a significant difference (p<0.001) between lenvatinib+gemcitabine and all other treatment groups. D. Individual tumor response for Experiment #2. Note in the lenvatinib +gemcitabine group, the slight regrowth from day 15 to 19, is suppressed when fresh lenvatinib was prepared.